AKT1 is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 is altered in 1.25% of pecoma patients [2].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD274 is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and pecoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MTOR is altered in 1.23% of pecoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PDGFRA is altered in 2.33% of pecoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC1 is altered in 8.54% of pecoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 is altered in 44.58% of pecoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].